Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Experts Underline Need to fight Stigmatization & Discrimination against People with Hepatitis at Conference Organized by Institute of Liver and Biliary Sciences (ILBS) - The Pharma Times | Pharma & Health Care News Portal
Categories: Uncategorized

Experts Underline Need to fight Stigmatization & Discrimination against People with Hepatitis at Conference Organized by Institute of Liver and Biliary Sciences (ILBS)

  • Institute of Liver and Biliary Sciences (ILBS) to host a conclave to bring together policy makers, health activists and social influencers on the eve of World Hepatitis Day
  • 4 crore Indians suffering from Hepatitis B; almost 1.2 crore suffering from Hepatitis C
  • Increasing vaccination coverage key to keep Hepatitis B at bay
  • Making Hepatitis C medicines available and easily accessible critical to fighting the disease
  • De-stigmatizing Hepatitis & creating awareness about prevention need of the hour

New Delhi, July 19, 2019: With 1.5 lakh deaths annually and almost 60 million Indians affected, viral hepatitis continues to be a serious public health concern. However, stigmatization and discrimination against patients hampers the country’s fight against the disease. The need to enact effective policies to fight prejudice and provide psycho social support to patients was at the centre of discussion as experts came together for a conference organized by the Institute of Liver and Biliary Sciences (ILBS).

India’s leading gastroenterologist & hepatologist Dr S K Sarin, Director of ILBS stressed the need to protect Hepatitis affected people from prejudice and biases while addressing a round table conference on ‘Hepatitis: Detection, Acceptance and Elimination’. He highlighted the need for fighting myths and misconceptions associated with the disease and underlined that Hepatitis B and C were viral infections that can be suppressed with proper treatment.

“Several instances of discrimination and rejection against people with Hepatitis have come to light over the past few years including in the field of medicine. Not only have people been denied jobs because of being diagnosed with hepatitis, many are also denied work visas to some countries if they are victims of Hepatitis B. This is why we feel that government should initiate strong policy measures to address discrimination and stigmatization of patients. Enacting a law to ensure Right to Live without discrimination must also be considered,” said Dr Sarin while addressing the conference along with Dr. Anil Agarwal (Head-Administration, ILBS), Lt. Col R S Singh (Deputy Head-Human Resources, ILBS), Dr. Neeraj Raizada (Asst. Professor-Epidemiology and Project Incharge-Empathy Campaign).

Notably, the Indian government has already enacted and enforced a law that prohibits discrimination against persons with HIV and AIDS. The Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency (AIDS) Syndrome (Prevention and Control) Act, 2017 lays down clear guidelines against discrimination and places obligations on establishments to safeguard their rights.

ILBS is all set to launch EMPATHY (Empowering People Against Hepatitis) campaign, which is a CSR initiative of Airport Authority of India (AAI), on World Hepatitis Day to address the issue. EMPATHY Conclave 2019 to be held on July 27 is part of a mega awareness drive on hepatitis initiated by ILBS and will bring together leading healthcare experts, law makers, government representatives, social influencers and prominent personalities from different strata of society to discuss effective ways of addressing the chronic disease.

“Through our EMPATHY conclave and associated campaign, we want to create a change in the mindset of the people,” he added.

According to estimates, 4 crore Indians are suffering from Hepatitis B while almost 1.2 crore have Hepatitis C. However, both Hepatitis B and C can be suppressed with proper treatment. Hepatitis B is vaccine preventable, just with 3 doses (for adults) at 0 day, 30 days and 6 months interval. Hepatitis C is curable, with 12-24 weeks of effective treatment India is the only country where medication for Hepatitis C is available at an affordable rate as compared to western countries.  Unfortunately, the stigma and discrimination associated with these infections is a significant hindrance to care-seeking, treatment compliance and mother to child transmission mainstreaming.

“Many patients with chronic hepatitis experience shame, decreased self-esteem, fear, depression, and isolation. There is a sense of guilt where they hide the disease or blame themselves for being careless about prevention. Hepatitis B and C are not communicable or sexually-transmitted disease. They can only happen through blood transfusion,” explained Dr Sarin, underlining that a series of myths and misconceptions about the disease contribute to the stigmatization of patients.

Several initiatives are currently being undertaken by the Government under the National Viral Hepatitis Control Program (NVHCP), to improve access to vaccines, diagnostics and treatment for patients and those at risk. It is vital to take steps to prevent the infection & keep your liver healthy. The campaign aims to bring together leading healthcare experts, law makers, government representatives, social influencers and prominent personalities from different strata of society to discuss effective ways of addressing the chronic disease.

Viral hepatitis has been recognized as an important public health problem not only in India but also across the world. According to WHO estimates, it caused 1.34 million deaths globally in 2015, a number comparable to deaths due to tuberculosis worldwide. Whereas, In India, it is estimated that 4 crore people are suffering from Hepatitis B and 0.6-1.2 crore people are suffering from Hepatitis C. While Tuberculosis remains as the leading infectious cause of death in India, there is an increasing trend in mortality due to Viral Hepatitis. In response the Government of India launched the National Viral Hepatitis Control program in India of 28th July 2018.

The campaign will focus on spreading awareness about HBV & HCV and address the stigma associated with the disease by encouraging dialogue among policy makers, program managers, care providers, civil society and the patients. The fear of being diagnosed or status being revealed to family members often keeps people away from getting tested, seeking effective treatment and preventive measures. This can lead to worsening health outcomes. ILBS has been spearheading a nation-wide campaign to make people aware about Hepatitis B & C. The cause is being implemented with support from the Airports Authority of India (AAI). Over the last year, the campaign has reached out to several public and private organizations engaging them in the cause. As part of the campaign, the work force in these organizations are also taking pledge for the cause and to make people know about the disease and encourage them to disapprove any kind of discrimination against those living with Hepatitis.

Corporate Comm India (CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Fortis Hospital, Bannerghatta Road Launches dedicated Parkinson’s Disease and Deep Brain Stimulation Clinic

-  This specialized division empowers patients with neurological disorders to reclaim their mobility through a…

17 hours ago

Milestone set in Indian Medical History – SSI Mantra Surgical Robotic System Performs the First-Ever Successful Surgery on One-Year-Old Infant

SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…

3 days ago

Manipal Hospital Ghaziabad organises Fire Safety Training to Enhance Emergency Response

Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…

1 week ago

Professor Dr Robert Zeiser receives DKMS Mechtild Harf Science Award 2024

DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…

2 weeks ago

Dr. Reddy’s launches drug-free migraine management device Nerivio® in Europe following successful launch in India

Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…

2 weeks ago

Ankura Hospital Doctors perform a successful Complex Lung Surgery on a 4-month-old Infant

 Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…

3 weeks ago